Dr. Strosberg Discusses Results for KEYNOTE-158

January 21, 2019

Jonathan R. Strosberg, MD, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab in patients with advanced neuroendocrine tumors.

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab (Keytruda) in patients with advanced neuroendocrine tumors (NETs).

The results were not encouraging with only 4 of the 107 patients responding, Strosberg says. All of the responders were PD-L1-negative, concluding that this was not a predictive biomarker. This trial did not show any clear direction in terms of what type of NET will respond tp pembrolizumab treatment.

The data shows that single-agent PD-1/PD-L1 inhibitor is not active in this patient population. Combinations or other options should be looked at in the future, Strosberg concludes.

View more from the 2019 Gastrointestinal Cancers Symposium


x